Evidence map›Paper›PMID 41531534›Full record

ArticleFrontiers in microbiology2025

Antibacterial potential of a new glucosaminidase from

Karla G Alvarez-Villagomez, Daniel Balleza, Carolina Peña-Montes, Itzel C Fonseca-Barrera, Patricia G Mendoza-García

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Karla G Alvarez-Villagomez *Unidad de Investigación y Desarrollo en Alimentos, TecNM/Instituto Tecnológico de Veracruz, Veracruz, Mexico.
Daniel Balleza *Unidad de Investigación y Desarrollo en Alimentos, TecNM/Instituto Tecnológico de Veracruz, Veracruz, Mexico.
Carolina Peña-MontesUnidad de Investigación y Desarrollo en Alimentos, TecNM/Instituto Tecnológico de Veracruz, Veracruz, Mexico.
Itzel C Fonseca-BarreraUnidad de Investigación y Desarrollo en Alimentos, TecNM/Instituto Tecnológico de Veracruz, Veracruz, Mexico.
Patricia G Mendoza-GarcíaUnidad de Investigación y Desarrollo en Alimentos, TecNM/Instituto Tecnológico de Veracruz, Veracruz, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: Through differential extraction of protein fractions associated with the membrane of this bacterial strain and in silico analysis, we report the compositional, physicochemical, and biochemical characterization of an enzyme with N-acetylglucosaminidase (NAGase) activity. Additionally, we determined the bactericidal activity of this enzymatic extract against two Gram-positive and two Gram-negative pathogens. We also evaluated ultrastructural changes in sensitive bacteria using scanning electron microscopy (SEM). Results: This NAGase activity shows a high specificity against Micrococcus lysodeikticus ATCC 4698 cell walls. The active protein has a molecular mass close to 110 kDa, a sequence of 935 residues, a possible transmembrane fragment close to the N-terminal end, and a profile of high intrinsic flexibility with high hydrophilicity, consistent with a possible topology for a peripheral membrane protein. The enzyme induces significant autolytic activity in Discussion: This NAGase has great potential as an enzybiotic, as an alternative to the use of conventional antibiotics. Showing little hemolytic activity, this protein has pharmacological potential against multidrug-resistant bacteria. We propose a mechanism of action in which this enzyme hydrolyzes GlcNAc units present in the cell wall of diverse pathogens.

Indexed as

autolysisenzybioticsN-acetylglucosaminidase (NAGase)Pediococcus acidilacticipeptidoglycan (PG) hydrolases

Identifiers

PMID41531534
PMCPMC12791037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.